Newron, Zambon deal

The companies extended to May 13 the option exercise period for Zambon to license rights to Parkinson's disease therapy safinamide worldwide, excluding Asian territories. Upon exercise of the option, Zambon would pay Newron an undisclosed payment and cover all development and regulatory costs in the territories. Zambon would also qualify for one seat on Newron's board. Newron would be eligible for regulatory milestones, plus double-digit royalties (see BioCentury, April 9). ...